Articles

Highlights in acute lymphoblastic leukaemia

BJH - volume 12, issue 5, september 2021

C. Graux MD, PhD

SUMMARY

The EHA congress is not only the opportunity to present or update the results of clinical trials, but it is also the occasion to present some fundamental research and to discuss certain themes that allow us rethinking the overall treatment strategy and monitoring of haematologic diseases.

(BELG J HEMATOL 2021;12(5):207-10)

Read more

Acute graft-versus-host disease: diagnosis, pathophysiology and prevention

BJH - volume 11, issue 4, june 2020

B. Vandenhove PhD student, L. Canti PhD student, H. Schoemans MD, PhD, Y. Beguin MD, PhD, prof. F. Baron , E. Willems MD, PhD, C. Graux MD, PhD, T. Kerre MD, PhD, S. Servais MD, PhD

SUMMARY

Acute graft-versus-host disease (aGVHD) remains a severe complication after allogeneic stem cell transplantation (alloHCT). It is a disregulated immune process, during which the immune cells of the donor attack the healthy tissues in the immunocompromised host. Over the past two decades, progress in understanding its pathophysiology have helped redefine aGVHD reactions and clinical presentations. Typically, the disease presents with serious inflammatory lesions mainly in the skin, gut and liver. Its severity is assessed by gathering clinical signs and dysfunctions of each organ. Despite standard prophylaxis regimens, aGVHD still occurs in approximately 30–60% of transplanted patients and remains a major cause of transplant-related morbidity and mortality. Hence, there is an urgent need for optimising preventive strategies. In this review, we give insights on how to make an accurate diagnosis and scoring assessment of aGVHD, propose a short overview of the current knowledge about its immunobiology and discuss the current and developing strategies for prevention.

(BELG J HEMATOL 2020;11(4):159–173)

Read more

P.46 Hepatitis E management in allogeneic Hematopoietic Stem Cell Transplant (HSCT) recipients: a case report

BJH - volume 11, issue Abstract Book BHS, february 2020

G. Crochet MD, M. Bourgeois , E. Collinge MD, H. Vellemans MD, M. André MD, PhD, A. Sonet MD, C. Graux MD, PhD

Read more

O.6 Multipotent mesenchymal stromal cells for poor graft function after allogeneic hematopoietic cell transplantation – a multicenter prospective study

BJH - volume 11, issue Abstract Book BHS, february 2020

S. Servais MD, PhD, prof. F. Baron , C. Lechanteur PhD, E. Baudoux MD, A. Briquet PhD, D. Selleslag MD, J. Maertens MD, PhD, X. Poiré MD, PhD, W. Schroyens MD, PhD, C. Graux MD, PhD, A. De Becker MD, R. Schots MD, PhD, P. Zachée MD, PhD, A. Ory , J. Herman , T. Kerre MD, PhD, Y. Beguin MD, PhD

Read more

O1 Prophylactic donor lymphocyte infusions after hematopoietic stem cell transplantation in high risk acute leukemia and myelodysplastic syndromes: a single-center retrospective study.

BJH - 2018, issue Abstract Book BHS, february 2018

E. Collinge MD, C. Graux MD, PhD, M. André MD, PhD, H. Labussière-Wallet , M. Michallet , G. Salles

Read more

PP06 Hereditary predisposition syndromes to malignant hemopathies (HPSMH)

BJH - 2018, issue Abstract Book BHS, february 2018

S. Dupriez , A. Ferrant , M-C. Vekemans MD, B. Brichard MD, PhD, L. Michaux MD, PhD, T. Connerotte MD, E. Van den Neste MD, PhD, C. Vermylen , L. Knoops MD, PhD, C. Graux MD, PhD, F. Duhoux MD, PhD, C. Lambert MD, X. Poiré MD, PhD, H.A. Poirel MD, PhD

Read more

O2 In Vitro Effects of BCR-ABL Tyrosine Kinase Inhibitors on Endothelial Cells Survival and Functions

BJH - 2018, issue Abstract Book BHS, february 2018

H. Haguet , J. Douxfils PhD, PharmD, C. Chatelain MD, C. Graux MD, PhD, F. Mullier PhD, PharmD, J-M. Dogné PhD, PharmD

Read more